TITLE

Assessing the Ability of Topiramate to Improve the Daily Activities of Patients With Migraine

AUTHOR(S)
Brandes, Jan Lewis; Kudrow, David B.; Rothrock, John F.; Rupnow, Marcia F. T.; Fairclough, Diane L.; Greenberg, Steven J.
PUB. DATE
October 2006
SOURCE
Mayo Clinic Proceedings;Oct2006, Vol. 81 Issue 10, p1311
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To assess the impact of topiramate on the daily activities of patients with migraine. PATIENTS AND METHODS: We performed a randomized, double-blind, placebo-controlled multicenter trial initiated on March 1, 2001, and completed on April 4, 2002. Patient-reported data from the Migraine Specific Questionnaire (MSQ) and the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) were collected at baseline and at weeks 8, 16, and 26 from an intent-to-treat population receiving either topiramate, 50, 100, or 200 mg/d, or placebo. Two activity-related MSQ domains (role restrictive [MSQ-RR] and role prevention [MSQ-RP]) and 2 activity-related SF-36 domains (role physical [SF36-RP] and vitality [SF36-VT]) were the prospectively designated secondary outcome measures. The changes in MSQ and SF-36 scores for each treatment group were calculated by measuring the area under the curve from week 8 (the beginning of the maintenance period) through week 26 of the double-blind phase, relative to the prospective baseline. A mixed-effect piecewise linear regression model was used to estimate average domain score over time. RESULTS: Patients receiving topiramate, 100 or 200 mg/d, had significantly reduced mean monthly (28-day) migraine frequency (P=.008 and P<.001, respectively) compared with placebo, but not patients receiving topiramate, 50 mg/d (P=.48). Topiramate significantly improved mean MSQ-RR domain scores (50 mg/d [P=.02], 100 mg/d [P<.001], and 200 mg/d [P<.001]) and mean MSQ-RP domain scores (50 mg/d [P=.007], 100 mg/d [P=.001], and 200 mg/d [P=.002]) vs placebo. Topiramate, 100 and 200 rag/d, significantly improved mean SF36-RP domain scores vs placebo (P=.02). Topiramate (all doses) improved SF36-VT domain scores, although not significantly vs placebo. Changes in prospectively designated domain scores were significantly correlated with changes in mean monthly migraine frequency (P≤.001 [MSQ domains], P≤.002 [SF-36 domains]). CONCLUSION: Patient-reported migraine-specific outcomes measured by the MSQ-RR and MSQ-HP domains improved significantly for those receiving topiramate (all doses) vs placebo. The SF36-RP domain scores improved significantly for patients receiving 100 or 200 mg/d of topiramate. Improvements in all 4 prospectively selected MSQ and SF-36 domains were significantly correlated with decreases in mean monthly migraine frequency.
ACCESSION #
23272663

 

Related Articles

  • The Effect of Migraine Prophylaxis on Migraine-Related Resource Use and Productivity. Láinez, Miguel J. A. // CNS Drugs;2009, Vol. 23 Issue 9, p727 

    In the US, it is estimated that up to 10% of men and 25% of women, particularly those aged 25-55 years, experience debilitating migraines, such that the condition presents an enormous economic burden for patients, health systems, employers and society. Migraine headache is a particularly...

  • Antiepileptic drug reduces migraine attacks.  // Nursing Standard;4/7/2004, Vol. 18 Issue 30, p10 

    Reports on the efficacy of antiepileptic drug, Topiramate, in migraine prevention. Characteristics of the drug; Reduction in the mean monthly migraine frequency of patients involved in the clinical trial for the drug.

  • A Randomized, Double-Blinded, Placebo-Controlled Trial of Intercostal Nerve Block After Percutaneous Nephrolithotomy. Honey, R. John D'A.; Ghiculete, Daniela; Ray, A. Andrew; Pace, Kenneth T. // Journal of Endourology;Apr2013, Vol. 27 Issue 4, p415 

    Background and Purpose: The optimal method of pain control after percutaneous nephrolithotomy (PCNL) remains controversial. We sought to determine whether intercostal nerve block with bupivicaine provided superior pain control, when compared with placebo, with a lower need for narcotics and...

  • Topiramate in the treatment of compulsive sexual behavior: case report. Khazaal, Yasser; Zullino, Daniele Fabio // BMC Psychiatry;2006, Vol. 6, p22 

    Background: Among the multiple mechanisms of action of topiramate, AMPA/kainate antagonism may be particularly interesting for the treatment of disorders characterized by conditioned cognitive and behavioral cue reactivity. Case presentation: We report the case of a patient consulting primarily...

  • Epilepsy drug works against hypertension.  // Cortlandt Forum;9/25/2005, Vol. 18 Issue 9, p19 

    Cites a study which found that obese hypertensives who took topiramate drug have lose weight and gain better blood pressure control. Division of obese hypertensives into placebo group and group that received topiramate; Occurrence of mild adverse effect on topiramate group; Mechanism by which...

  • Migraine treatment - a financial headache.  // PharmaWatch: Monthly Review;Mar2005, Vol. 4 Issue 3, p19 

    The article presents a study involving the percentage of people suffering from migraine worldwide. Migraine attacks can interfere greatly with the everyday lives of sufferers. The most commonly used current treatment are simple analgesics like triptan Excedrin. Despite the fact that triptans are...

  • Antiepileptic drugs in migraine prophylaxis. Mazzotta, Giovanni; Floridi, Francesca; Alberti, Andrea; Sarchielli, Paola // Journal of Headache & Pain;Nov 2004 Supplement 2, Vol. 5, ps67 

    Research in the field of headache treatment has experienced a marked impetus in the last few years. In the era of the triptans, the treatment modality of this disease has been revolutionised, and though most of the studies conducted have investigated the symptomatic treatment of migraine, less...

  • Rizatriptan: A Pharmacoeconomic Review of its Use in the Acute Treatment of Migraine. McCormack, Paul L.; Foster, Rachel H. // PharmacoEconomics;2005, Vol. 23 Issue 12, p1283 

    Rizatriptan (Maxalt®; Maxalt-MLT®; Maxalt-Melt®) is an oral serotonin 5-HT1B/1D receptor agonist (triptan) used in the acute treatment of migraine with or without aura in adults. Rizatriptan 5mg and 10mg are effective in relieving the symptoms of migraine and the 10mg dose provided...

  • Topiramate in migraine prophylaxis: data from a pooled analysis and open-label extension study. Bussone, G.; Usai, S.; D'Amico, D. // Neurological Sciences;May2006 Supplement 2, Vol. 27, ps159 

    Topiramate is approved for the preventive treatment of migraine in several countries based on the results of three large randomised, double-blind studies that showed that this compound was significantly more effective than placebo in migraine prophylaxis. We review the results of two studies:...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics